Benefits of Implantable Cardioverter–Defibrillator for Secondary Prevention in Patients With Organic Heart Disease
Annals of Noninvasive Electrocardiology · 2026
DOI: 10.1111/anec.70131 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Noninvasive Electrocardiology, 2026. Verfasst von Rie Akagawa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. Hauptthemen laut MEDLINE: Defibrillators, Implantable, Death, Sudden, Cardiac, Secondary Prevention, Tachycardia, Ventricular. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Implantable cardioverter‐defibrillators (ICD) are first‐line treatment to prevent sudden cardiac death due to recurrent ventricular tachycardia and fibrillation (VT/VF). However, some patients with organic heart disease (OHD) die without ever receiving appropriate ICD therapy. This study aimed to identify predictors of death without appropriate ICD therapy in patients with OHD who received ICD or cardiac resynchronization therapy with a defibrillator (CRT‐D) for secondary prevention.
Methods
We analyzed consecutive patients who received ICD/CRT‐D for secondary prevention between 2000 and 2022. Patients without OHD or those alive without appropriate ICD therapy were excluded. The “no‐benefit group” included patients who died or developed severe disability without appropriate ICD therapy or those who died within 1 year after their first appropriate therapy. The “benefit group” included patients who survived > 1 year after appropriate therapy. Clinical characteristics were compared between the groups.
Results
Of the 170 patients analyzed (median follow‐up: 9.1 years), 43 (25%) were classified into the no‐benefit group (30 died without appropriate therapy, 10 died within 1 year of first appropriate therapy, and 3 developed severe disability without appropriate therapy). Multivariate analyses identified age > 70 years and history of VF as independent predictors of “no benefit.” Among patients with VF aged ≥ 70 years, 71% were classified into the no‐benefit group.
Conclusions
Although 75% of patients benefited from ICD therapy for secondary prevention, elderly patients with VF may gain limited benefits from ICD implantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
- Niigata University School of Medicine, Niigata, Japan.
ORCID-Profile: Sou Otsuki, Yuki Hasegawa
Zitieren
APA
Akagawa, R., Otsuki, S., Sakurazawa, M., Kato, A., Furuse, H., Suzuki, N., Ikami, Y., Hasegawa, Y., Chinushi, M., & Inomata, T. (2026). Benefits of Implantable Cardioverter–Defibrillator for Secondary Prevention in Patients With Organic Heart Disease. Annals of Noninvasive Electrocardiology. https://doi.org/10.1111/anec.70131
Vancouver
Akagawa R, Otsuki S, Sakurazawa M, Kato A, Furuse H, Suzuki N, et al. Benefits of Implantable Cardioverter–Defibrillator for Secondary Prevention in Patients With Organic Heart Disease. Annals of Noninvasive Electrocardiology. 2026. doi:10.1111/anec.70131
BibTeX
@article{Akagawa2026,
author = {Akagawa, Rie and Otsuki, Sou and Sakurazawa, Minori and Kato, Atsushi and Furuse, Hironori and Suzuki, Naomasa and Ikami, Yasuhiro and Hasegawa, Yuki and Chinushi, Masaomi and Inomata, Takayuki},
title = {Benefits of Implantable Cardioverter–Defibrillator for Secondary Prevention in Patients With Organic Heart Disease},
journal = {Annals of Noninvasive Electrocardiology},
year = {2026},
doi = {10.1111/anec.70131}
}
EUVIMED